Skip to content

Celcuity CELC Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
Exelixis logo
ExelixisEXEL
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Celcuity's preferred stock, shares issued?
Celcuity (CELC) reported preferred stock, shares issued of $0 in Q1 2026.
How has Celcuity's preferred stock, shares issued changed year-over-year?
Celcuity's preferred stock, shares issued decreased by 100.0% year-over-year, from $317.58K to $0.